Core Insights - GSK plc reported fourth-quarter 2025 core earnings of 68 cents per American depositary share (ADS), exceeding the Zacks Consensus Estimate of 64 cents, with a 10% year-over-year increase on a reported basis and 14% at a constant exchange rate (CER) [1][9] - Quarterly revenues rose 6% on a reported basis and 8% at CER to $11.46 billion (£8.62 billion), driven by increased sales of HIV, oncology, and respiratory medicines, surpassing the Zacks Consensus Estimate of $11.19 billion [2][9] Segment Performance - GSK operates under three segments: General Medicines, Specialty Medicines, and Vaccines. Specialty Medicines sales increased by 18%, while Vaccine sales rose by 4%. General Medicines sales fell by 1% [3] - Specialty Medicines drove top-line growth, with HIV sales up 11% due to increased demand for Dovato and long-acting medications like Apretude and Cabenuva [4][5] - Oncology sales surged by 42%, primarily due to strong demand for Jemperli and Ojjaara/Omjjara, with Jemperli sales increasing by 79% following label expansion [6][7] - Respiratory drug Nucala sales rose by 19%, driven by strong performance in the U.S. market, while Benlysta sales increased by 26% [8] Vaccine Sales - GSK's vaccine sales growth was driven by increased uptake of meningitis, RSV, and shingles vaccines in ex-U.S. markets, with Shingrix sales rising by 20% [10] - Established vaccine sales declined by 13% due to divested brands and lower sales for Rotarix and Synflorix [11] General Medicines - General Medicines showed stable performance with Trelegy Ellipta sales up 14%, while Anoro Ellipta and Relvar/Breo Ellipta sales fell by 10% and 16%, respectively [12][13] Operating Expenses and Guidance - Core selling, general, and administration costs rose by 2% to £2.68 billion, while core research and development expenses increased by 18% to £2.12 billion [14] - GSK expects sales growth of 3-5% in 2026, with specialty medicines projected to grow by a low double-digit percentage at CER [15] Future Outlook - GSK has a total of 58 assets in clinical development, with two major product approvals expected this year [21][22] - The company aims to generate sales of more than £40 billion by 2031, reflecting a positive long-term outlook [18]

Core Insights - RTX Corporation (RTX) stock has increased by 30.2% over the past six months, outperforming the Zacks Aerospace-Defense industry's growth of 8.7% and the broader Zacks Aerospace sector's gain of 9.4% [1][8] - Other industry players like Huntington Ingalls Industries (HII) and General Dynamics (GD) have also shown strong performance, with HII shares rising by 58.6% and GD by 13.2% in the same period [2] Business Developments - RTX's recent stock performance is supported by positive developments in its defense and commercial aerospace segments [4] - In February 2026, RTX was selected by DARPA to develop an advanced sensing and targeting system aimed at protecting commercial shipping and naval logistics vessels from emerging threats [5] - RTX signed multiple memoranda of understanding with the Singapore Economic Development Board at the Singapore Airshow, reinforcing its commitment to Singapore as a key hub for aerospace activities [6] - Additionally, RTX signed two FlightSense renewal agreements with All Nippon Airways, strengthening its commercial aerospace services business [9] Financial Estimates - The Zacks Consensus Estimate for RTX's 2026 sales indicates a year-over-year growth of 5.2%, with earnings expected to increase by 8% [10] - Current estimates for RTX's 2026 sales are projected at $93.21 billion, with a high estimate of $93.94 billion and a low of $92.60 billion [11] - The earnings per share (EPS) for 2026 is estimated at $6.79, reflecting a year-over-year growth of 7.95% [12] Valuation Metrics - RTX's forward 12-month price-to-earnings (P/E) ratio is 29.76X, which is lower than the industry average of 32.30X, indicating a more attractive valuation relative to expected earnings growth [13] - In comparison, HII and GD have forward P/E ratios of 24.48X and 21.53X, respectively, suggesting they are trading at a discount compared to RTX [14] Liquidity Position - RTX has a current ratio of 1.03, indicating sufficient capital to meet short-term debt obligations [15]

Core Viewpoint - Investors in Minerals Technologies Inc. (MTX) should closely monitor the stock due to significant movements in the options market, particularly the high implied volatility of the Feb 20, 2026 $45 Put option [1] Group 1: Implied Volatility - Implied volatility indicates the market's expectations for future stock movement, with high levels suggesting potential significant price changes or upcoming events that could lead to a rally or sell-off [2] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of the option's value if the stock does not move as expected [4] Group 2: Analyst Sentiment - Minerals Technologies currently holds a Zacks Rank of 3 (Hold) within the Chemical – Specialty industry, which is positioned in the bottom 25% of the Zacks Industry Rank [3] - Over the past 30 days, no analysts have raised their earnings estimates for the current quarter, while one analyst has lowered the estimate, resulting in a decrease of the Zacks Consensus Estimate from $1.36 to $1.26 per share [3]

Core Insights - Jacobs Solutions Inc. reported strong first-quarter fiscal 2026 results, with adjusted earnings and revenues exceeding expectations and showing year-over-year growth [1][4] Financial Performance - Adjusted EPS was $1.53, surpassing the Zacks Consensus Estimate of $1.52 by 0.7%, and increased from $1.33 in the same quarter last year [4] - Gross revenues reached $3.29 billion, exceeding the consensus mark of $3.18 billion by 3.5% and growing 12.3% year over year [4] - Adjusted net revenues were $2.25 billion, up 8.2% year over year [4] - Adjusted operating profit grew 8.2% to $299.6 million, with an adjusted operating margin remaining flat at 13.3% [5] - Adjusted EBITDA was $302.6 million, up 7.3% year over year, with a margin of 13.4%, down 10 basis points from the previous year [5] Segment Performance - Infrastructure & Advanced Facilities segment revenues totaled $2.94 billion, a 12% increase year over year, with adjusted net revenues of $1.9 billion, up 6.9% [6] - PA Consulting segment generated $354.4 million in revenues, a 15.5% increase from the previous year [8] Backlog and Demand - Fiscal first-quarter backlog increased 20.6% year over year to $26.3 billion, indicating strong project wins and a book-to-bill ratio of 1.4x [5][9] - The backlog at the end of the quarter was $25.9 billion, up from $21.48 billion a year ago [7] Cash Flow and Balance Sheet - Cash and cash equivalents at the end of the quarter were $1.55 billion, up from $1.24 billion at the end of fiscal 2025 [11] - Net cash provided by operating activities totaled $380.8 million, significantly up from $107.5 million in the same period last year [12] - Free cash flow was $364.9 million, up from $97.1 million a year ago [12] Future Outlook - Jacobs raised its fiscal 2026 guidance, expecting adjusted net revenues to grow between 6.5% and 10% and adjusted EPS to be between $6.95 and $7.30 [13] - The company anticipates a free cash flow margin ranging from 7% to 8.5% [14]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057), a leading and fast-growing express delivery company in China ("ZTO" or the "Company"), today announced the pricing of US$1.5 billion in aggregate principal amount of convertible senior notes due 2031 (the "Notes"). The Notes have been offered in offshore transactions outside the United States to non-U.S. persons that are "qualified institutional buyers" (as defined in Rule 144A under the United States Securities Ac ...

Tesla Stock: EV Giant Begins 2026 With Solid China Sales As Musk Appears To Shift Focus | Investor's Business DailyBREAKING: [Eli Lilly Surges As Obesity Drugs Fuel Strong Earnings, Guidance]---Tesla (TSLA) sales of China-made electric vehicles in January increased more than 9% compared to a year ago, representing a decent start to the year even as CEO Elon Musk seems to be shifting focus away from EV manufacturing to focus more on autonomous vehicles and humanoid robots. China-made Tesla Model 3 and Model ...

Core Viewpoint - The article summarizes significant research calls from Wall Street, highlighting upgrades for various companies that could influence market movements [1] Group 1: Upgrades - BofA upgraded Five Below (FIVE) to Buy from Underperform with a price target of $233, increased from $158, citing improvements under new leadership [2] - Compass Point upgraded PayPal (PYPL) to Neutral from Sell with a price target of $51, indicating that shares are reflecting "peak uncertainty" following the earnings report [2] - Citizens upgraded Airbnb (ABNB) to Outperform from Market Perform with a price target of $160, anticipating multiple catalysts that could enhance performance [2] - Mizuho upgraded Booking Holdings (BKNG) to Outperform from Neutral with an unchanged price target of $6,000, suggesting a 30% upside and viewing the recent pullback as a buying opportunity [2] - Baird upgraded GE Vernova (GEV) to Outperform from Neutral with a price target of $923, up from $701, believing the energy infrastructure cycle is still in early stages and GE Vernova will benefit significantly [2]

The US labour market showed little momentum at the start of 2026, with private-sector hiring falling short of even modest expectations, according to a report released on Wednesday by payrolls firm ADP. ...

Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" price pressure forces it to slash the cost of its blockbuster Wegovy drug in ... ...